Gastrointestinal cancer (N = 19)
|
Khorana (29) |
2003 |
Prosp. |
131 (69/53) |
131 Colon |
11 (118) |
5 |
NR |
>2% |
Data extrapolated, Survival curve |
Stag., OS |
Indeterminate |
Tan (12) |
2005 |
Retro. |
60 (35/25) |
60 Colon |
26 (34) |
NR |
NR |
>25% |
Data extrapolated, Survival curve |
Stag., OS |
Negative |
Bacman (30) |
2007 |
NR |
310 (189/121) |
310 Colon |
178 (132) |
7.5 |
NR |
NR |
Data extrapolated |
OS |
Indeterminate |
Forssell (15) |
2007 |
Retro. |
488 (271/217) |
488 Colon |
207 (254) |
NR |
NR |
NR |
Data extrapolated, Reported in text |
Stag., OS |
Indeterminate, negative |
Zhou (18) |
2010 |
NR |
160 (94/66) |
160 Colon |
NR |
5 |
Yes |
20% |
Data extrapolated, reported in text |
Stag., OS |
Negative |
Ishigami (31) |
2003 |
Retro. |
97 (72/25) |
97 Stom |
67 (30) |
NR |
NR |
>200 / HPF |
Data extrapolated, Survival curve |
Stag., OS |
Indeterminate, positive |
Ohno (10) |
2005 |
Retro. |
84 (57/27) |
84 Stom |
41 (43) |
NR |
Yes |
>4.7% |
Survival curve |
DFS |
Negative |
Hass (32) |
2009 |
Prosp. |
52 (40/12) |
50 Stom |
39 (13) |
5.9 |
NR |
NR |
Reported in text |
DFS |
Indeterminate |
Kawahara (33) |
2010 |
NR |
111 (77/34) |
111 Stom |
36 (75) |
NR |
NR |
NR |
Reported in text |
OS |
Positive |
Osinsky (34) |
2011 |
Prosp. |
105 (71/34) |
105 stom |
48 (57) |
NR |
NR |
>23.0% |
Reported in text |
OS |
Positive |
Zhu (22) |
2008 |
Retro. |
105 (96/9) |
105 Liver |
86 (19) |
1.84 |
NR |
>20% |
Data extrapolated, reported in text |
Stag., OS, DFS |
Indeterminate, positive |
Li (24) |
2009 |
Retro. |
302 (260/42) |
302 Liver |
237 (65) |
4.83 |
NR |
>20% |
Data extrapolated, reported in text |
Stag., OS, DFS |
Indeterminate, negative |
Ding (35) |
2009 |
Retro. |
107 (87/20) |
107 Liver |
98 (39) |
2.5 |
MR |
>23% |
Reported in text |
OS, DFS |
Positive |
Kuang (36) |
2009 |
Retro. |
262 (NR) |
206 Liver |
249 (13) |
NR |
NR |
NR |
Reported in text |
OS, DFS |
Positive |
Ju (23) |
2009 |
Retro. |
130 (112/18) |
130 Liver |
66 (64) |
2.65 |
NR |
>20% |
Reported in text |
Stag., OS, DFS |
Positive |
Koide (9) |
2002 |
Retro. |
56 (42/14) |
56 Esophagus |
30 (26) |
NR |
NR |
NR |
Data extrapolated, survival cure |
Stag., OS |
Indeterminate, negative |
Guo (19) |
2007 |
NR |
137 (103/34) |
137 Esophagus |
86 (51) |
NR |
NR |
>25% |
Reported in text |
Stag., OS |
Indeterminate, positive |
Kurahara (37) |
2012 |
Retro. |
76 (52/24) |
52 Pancreas |
29 (47) |
NR |
Yes |
NR |
Survival curve |
OS, OSb
|
Indeterminate |
Hasita (38) |
2010 |
NR |
39 (27/12) |
55 Bile duct |
29 (10) |
3.33 |
Yes |
NR |
Data extrapolated, survival curve |
Stag., OS, DFS, Stag.b, OSb, DFSb
|
Indeterminate |
Urogenital cancer (N = 20)
|
Leek (39) |
1996 |
Retro. |
101 (0/101) |
5 Breast |
NR |
NR |
NR |
MD > = 12 |
Reported in text |
OS, DFS |
Positive |
Toi (40) |
1999 |
NR |
229 (0/229) |
229 Breast |
NR |
4 |
Yes |
NR |
Survival curve |
DFS |
Indeterminate |
Valkovic (41) |
2002 |
NR |
97 (0/97) |
97 Breast |
82 (15) |
NR |
NR |
NR |
Data extrapolated |
Stag. |
Indeterminate |
Bolat (42) |
2006 |
Retro. |
78 (0/78) |
78 Breast |
38 (10) |
NR |
NR |
NR |
Data extrapolated |
Stag. |
Indeterminate |
Mahmound (43) |
2012 |
Retro. |
1902 (0/1902) |
1902 Breast |
220 (1682) |
NR |
NR |
NR |
Data extrapolated, survival curve |
Stag., DFS |
Positive, indeterminate |
Salvesen (44) |
1999 |
Prosp. |
60 (0/60) |
60 Endometrium |
50(10) |
11 |
NR |
NR |
Data extrapolated, reported in text |
Stag., OS |
Positive, indeterminate |
Hashimoto (45) |
2000 |
NR |
109 (0/109) |
109 Endometrium |
56(53) |
4.58 |
NR |
NR |
Data extrapolated |
Stag., DFS |
Indeterminate |
Ohno (11) |
2004 |
Retro. |
70 (0/70) |
70 Endometrium |
NR |
NR |
NR |
MD >10.7 |
Survival curve |
DFS |
Negative |
Soeda (46) |
2008 |
Retro. |
76 (0/76) |
76 Endometrium |
59(17) |
6.83 |
NR |
NR |
Survival curve |
OS, DFS |
Positive, indeterminate |
Espinosa (47) |
2010 |
NR |
64 (0/64) |
64 Endometrium |
23(26) |
NR |
NR |
NR |
Data extrapolated |
Stag.b
|
Indeterminate |
Lissbrant (48) |
2000 |
Retro. |
85 (85/0) |
85 Prostate |
75(10) |
NR |
NR |
> = 0.97% |
Survival curve |
Stag., OS |
Indeterminate |
Shimura (49) |
2000 |
NR |
81 (81/0) |
81 Prostate |
67(13) |
3.9 |
NR |
NR |
Reported in text |
DFS |
Indeterminate |
Nonomura (50) |
2011 |
NR |
131 (131/0) |
131 Prostate |
30(41) |
2.9 |
NR |
MD > = 22 |
Survival curve |
DFS |
Positive |
Heller (51) |
2002 |
Retro. |
24 (0/24) |
24 Cervix |
20/4 |
NR |
NR |
NR |
Data extrapolated |
Stag. |
Indeterminate |
Kawanaka (52) |
2008 |
Retro |
73 (0/73) |
73 Cervix |
22/51 |
NR |
Yes |
MD > = 55 |
Survival curve |
DFS |
Indeterminate |
Hanada (53) |
2000 |
NR |
63 (51/12) |
63 Bladder |
42/21 |
5.4 |
Yes |
MD > = 67 |
Data extrapolated, reported in text |
Stag., OS |
Positive |
Takayama (54) |
2009 |
NR |
41 (38/3) |
41 Bladder |
NR |
25 |
NR |
> = 4 |
Reported in text |
DFS |
Positive |
Tanaka (55) |
2004 |
NR |
89 (0/89) |
89 Ovary |
22/67 |
6.8 |
NR |
> = 25% |
Data extrapolated, reported in text, survival curve |
Stag., OS, DFS |
Negative, positive, indeterminate |
Wan (25) |
2009 |
NR |
67 (0/67) |
67 Ovary |
0/67 |
NR |
NR |
>20% |
Survival curve |
OS |
Positive |
Chai (20) |
2008 |
NR |
99 (42/57) |
99 Uroth |
NR |
NR |
NR |
>20% |
Reported in text |
OS, DFS |
Indeterminate, positive |
Lung cancer (N = 10)
|
Takanami (56) |
1999 |
Retro. |
113 (66/47) |
113 Lung |
61/52 |
NR |
NR |
MD>32 |
Survival curve |
OS |
Positive |
Chen (57) |
2005 |
NR |
41 (27/14) |
41 Lung |
23/18 |
NR |
NR |
MD> = 163 |
Survival curve |
DFS |
Indeterminate |
Welsh (13) |
2005 |
Retro. |
175 (116/59) |
175 Lung |
123/38 |
NR |
Yes |
NR |
Data extrapolated |
Stag., DFS |
Negative |
Zeni (58) |
2007 |
NR |
50 (43/7) |
43 Lung |
NR |
NR |
NR |
>16.3% |
Reported in text, survival curve |
Stag., OS |
Positive |
Kawai (16) |
2008 |
NR |
199 (139/60) |
199 Lung |
NR |
NR |
NR |
NR |
Reported in text |
OS |
Negative |
Ohri (17) |
2009 |
Retro. |
40 (16/24) |
40 Lung |
34/6 |
NR |
NR |
NR |
Survival curve |
OS |
Negative |
Al-shibli (59) |
2009 |
Retro. |
371 (253/82) |
371 Lung |
303/32 |
8 |
NR |
> = 25% |
Data extrapolated, survival curve |
OS, DFS |
Indeterminate |
Ma (26) |
2010 |
NR |
50 (40/10) |
50 Lung |
33/17 |
NR |
NR |
>20% |
Reported in text |
OSa, OSb
|
Indeterminate |
Ohtaki (60) |
2010 |
Prosp. |
170 (85/85) |
170 Lung |
NR |
10.1 |
NR |
NR |
Data extrapolated |
Stag., OS |
Positive |
Zhang (61) |
2011 |
Retro. |
65 (38/27) |
65 Lung |
38/27 |
NR |
Yes |
TAM counts >102 |
Survival curve |
OS |
Positive |
Head and neck cancer (N = 4)
|
Liu (21) |
2008 |
NR |
112 (93/19) |
112 Oral |
50/62 |
NR |
NR |
>20% |
Data extrapolated, survival curve |
Stag., OS |
Positive |
Fujii (62) |
2012 |
NR |
108 (31/10) |
108 Oral |
46/62 |
NR |
NR |
> = 2/HPF |
Data extrapolated, reported in text |
Stag., stag.b, OSb
|
Positive, indeterminate, positive |
Peng (14) |
2006 |
NR |
60 (38/22) |
60 Oral |
15/45 |
NR |
NR |
> = 63.7/HPF |
Data extrapolated |
OS |
Negative |
Lin (63) |
2011 |
NR |
84 (77/7) |
84 Lar |
30/54 |
NR |
NR |
> = 10/HPF |
Data extrapolated, reported in text |
Stag., OS, DFS |
Indeterminate, indeterminate, positive |
Thyroid cancer (N = 1)
|
Ryder (64) |
2008 |
NR |
37 (13/24) |
37 Thyr |
5/32 |
NR |
Yes |
> = 10/HPF |
Survival curve |
OS |
Positive |
Mesothelioma (N = 1)
|
Burt (65) |
2011 |
Retro. |
667 (531/136) |
667 Meso |
64/603 |
NR |
Yes |
NR |
Reported in text |
OS |
Indeterminate |